Aadi Bioscience, Inc. (AADI) Misses Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Aadi Bioscience, Inc. (AADI) Misses Q2 EPS by 12c

Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update

August 10, 2022 8:00 AM EDT

FYARRO® (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022

PRECISION 1 Phase 2 tumor-agnostic registration-directed trial continues enrollment and rapid site activation at major cancer centers and large community networks; preliminary data expected 1H23

Conference call to be held today at 8:30 am EDT

LOS ANGELES, Aug. 10, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for... More